~~<i id='9D29109A65'><strike id='9D29109A65'><tt id='9D29109A65'><pre id='9D29109A65'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

author：explore 2025-08-12 06:42:55 - browse：686

The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Generate Biomedicines machine learning biotech raises $273M

focus

leisure time

hotspot

focus

There’sapanelof20nutritionexpertsthathasoutsizedinfluenceontheAmericandiet—andthefoodindustryhaswork

WSS

HHS secretary Becerra pressed on Change HealthCare cyberattack

Acelyrin, a rare IPO success, stumbles in its first big test

UCLA team creates talking throat patch for voice disorders

Regeneron agrees to White House price limits on anti

How medical schools plan to diversify without affirmative action

FDA advisers back CAR

explore

explore

focus

Activists slam private health insurers over coverage restrictions

Regeneron agrees to White House price limits on anti

Walensky prepares to leave CDC — and Congress — behind

Acelyrin, a rare IPO success, stumbles in its first big test

Affirmative action in medical school literally saved lives

EPA limits use of carcinogenic gas for sterilizing medical devices

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Food makers to regulators: Ultra

23andMe had bad news about my health. I wish a person had delivered it

Change Healthcare outage fallout shows need for new oversight

focus

Food makers to regulators: Ultra

Why depression after traumatic brain injury is distinct

How medical schools plan to diversify without affirmative action

Amid AI frenzy, a top HHS official's quest to create safeguards

Why scientists need input from humanists on sensitive research

As AI in medicine takes off, can 'human in the loop' prevent harm?

leisure time

hotspot

hotspot

focus